Alanna Church, MD (she/her/hers)
Associate Director, Laboratory for Molecular Pediatric Pathology (LaMPP)
Boston Children's Hospital
Boston, Massachusetts, United States
Descrption: The 2018 College of American Pathologists (CAP) / International Association for the Study of Lung Cancer (IASLC) / AMP Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors guideline is currently undergoing a revision and update. This revision process reviews published evidence since 2018 that may change the strength of existing guideline recommendations. It also expands the guideline, providing new recommendations to address new biomarkers and clinical scenarios. The 2024 draft recommendation statements have recently completed an international open public comment period. Project progress updates will be provided in this session, along with the opportunity for an extended panel discussion with CAP/IASLC/AMP Lung Guideline Expert Panelists.
Learning Objectives:
- Receive update on 2018 CAP/IASLC/AMP Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors guideline revision currently in progress.
- Review results of open public comment period of the 2024 draft recommendation statements.
- Discuss and provide feedback regarding the upcoming guideline and emerging biomarkers addressed with a panel of Lung Guideline Expert Panelists.
If this session topic is of interest to you, please consider looking at the following course on AMP EDucation (AMPED™ Online)
Title: STK11 and KEAP1 Mutations in Lung Cancer
Please Click Here to Learn More.
Breakout Speaker: Neal Lindeman, MD (he/him/his) – Weill Cornell Medicine/NewYork-Presbyterian Hospital
Breakout Panelist: Sinchita Roy Chowdhuri, MD PhD – The University of Texas MD Anderson Cancer Center
Breakout Panelist: Laura Tafe, MD (she/her/hers) – Dartmouth-Hitchcock Medical Center